2 years ago

In this video, Dr. Goel discusses the latest groundbreaking study on a new medication called "donanemab," a monoclonal antibody targeting amyloid and Tau proteins.

Learn more about Donanemab
→ https://jamanetwork.com/journals/jama/fullarticle/2807533?guestAccessKey=855d51a0-c676-46f8-8bb3-1ecaa471d5eb&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=071723%20[jamanetwork.com]

📚 PURCHASE DR. SANJEEV GOEL'S BOOK "The Top 10 Must Do Peak Human Biohacks of 2023"📚
→ iBooks: https://books.apple.com/ca/book/top-10-must-do-peak-human-biohacks-of-2023/id6448680046
→ Kobo: https://www.kobo.com/ca/en/ebook/the-top-10-must-do-peak-human-biohacks-of-2023
→ Amazon - https://www.amazon.com/dp/B0C1J2N1YF

********************

Visit our website: https://peakhuman.ca/?v=3e8d115eb4b3
Shop here: https://peakhuman.ca/shop/
SUBSCRIBE TODAY: https://bit.ly/PeakHumanLabs

Published in Jama on July 17th, this randomized clinical trial involved over 1700 patients with early Alzheimer's disease and showed promising results. The medication demonstrated a significant decrease in disease progression, with patients experiencing up to a 30% reduction in symptoms over an 18-month period. Join Dr. Goyle as he dives into the key points of the study and highlights the potential impact of this new treatment. Don't miss out—subscribe to our channel for more informative updates on the battle against Alzheimer's. Leave your comments and thoughts below! Together, we can make a difference in the fight against this devastating disease.
******************

TIMESTAMP
0:00 - Intro
0:27 - Highlighting a new study on Alzheimer's medication
0:48 - Introducing the medication "donanemab"
0:53 - Medication targets amyloid and Tau proteins
0:59 - Overview of the study and its scope
1:01 - Key points of the study explained
1:20 - Significant progression decrease with the medication
1:31 - Approximately 30% reduction in disease progression
1:42 - Emphasizing the effectiveness of the medication
1:58 - Encouraging audience engagement and subscriptions
2:05 - Conclusion